GÖTEBORG, Sweden & RADNOR, Penn.--(BUSINESS WIRE)--Regulatory News:
Cortendo AB [ticker: CORT on NOTC-A], a biopharmaceutical company developing and commercializing products at the intersection of orphan diseases and endocrinology disorders, today announced that Matthew Pauls, President and CEO, will present at the 13th Annual BIO Investor Forum. The presentation is at the Palace Hotel in the Sea Cliff room on Oct. 7, 2014, at 3:00 p.m. PST in San Francisco, CA.
Pauls will present an update on the company and its lead asset, NormoCort (COR-003), which is being studied to treat Cushing’s syndrome in the international SONICS trial, a 90-patient, multi-site, open label Phase 3 study. The first patients enrolled in the SONICS trial in August.
The presentation will be available on the “Presentations” page in the Resources section of the company’s website at www.cortendo.com after the conference.
Cortendo AB is a global biopharmaceutical company incorporated in Sweden and based in the United States. The Company’s strategic focus is to be the global leader in developing and commercializing products at the intersection of Orphan Diseases and Endocrinology Disorders. Cortendo aims to become the leader in the field of cortisol inhibition, with the lead drug candidate, NormoCort (COR-003), in a Phase 3 global clinical trial for the treatment of Cushing’s Syndrome. The company’s intent is to independently commercialize its Orphan/Endocrine assets in key global markets, and when necessary, partner non-strategic product opportunities, such as diabetes, at relevant development stages.
Risk and uncertainty
The development of pharmaceuticals carries significant risk. Failure may occur at any stage during development and commercialization due to safety or clinical efficacy issues. Delays may occur due to requirements from regulatory authorities, difficulties in recruiting patients into clinical trials due to physician or patient preferences or competing products, not anticipated by the company. There is no assurance that Cortendo will receive marketing and regulatory approvals necessary to commercialize or produce NormoCort (COR-003) or other products. Regulatory approvals may be denied, delayed, limited or revoked.
The commercial success of NormoCort (COR-003), if approved in a territory, cannot be predicted with certainty. In addition, Cortendo may face the risk of interrupted supply of NormoCort (COR-003) for clinical or commercial use from the subcontractors Cortendo has contracted.
Cortendo Forward-looking Statements
This press release contains forward-looking statements concerning Cortendo that involve a number of risks and uncertainties. All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, plans, projects to enhance efficiency, outcomes of products development, future capital expenditures, liquidity requirements and objectives of management for future operations, may be deemed to be forward looking statements. These forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward looking statements. Given these risks and uncertainties, investors should not place any undue reliance on forward looking statements as a prediction of actual results. None of these forward looking statements constitutes a guarantee of the future occurrence of such facts and data or of actual results. These statements are based on data, assumptions and estimates that the Company believes are reasonable. The forward looking statements contained in this document are made only as of the date hereof. The Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this press release to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions or circumstances on which any forward looking statement contained in this press release is based.
|Cortendo AB (publ)|
|SE-433 21 Partille|
|Tel. / Fax. +46 (0)31-263010|
|555 East Lancaster Avenue|
|Radnor, PA 19087|
|Tel. +1 610-254-9200|
|Fax. +1 610-254-9245|
This information was brought to you by Cision http://news.cision.com